Insmed Inc (NASDAQ:INSM) shares traded -2.21% lower at $99.49 on Wall Street last session.
INSM stock price is now 28.34% away from the 50-day moving average and 33.22% away from the 200-day moving average. The market capitalization of the company currently stands at $18.90B.
With the price target of $105, Jefferies recently initiated with Buy rating for Insmed Inc (NASDAQ: INSM). On February 25, 2025, RBC Capital Mkts recently initiated its ‘Outperform’ rating on the stock quoting a target price of $100, while ‘Truist’ rates the stock as ‘Buy’
In other news, Bonstein Sara, Chief Financial Officer sold 57,765 shares of the company’s stock on Jun 23 ’25. The stock was sold for $5,879,089 at an average price of $101.78. Upon completion of the transaction, the Chief Financial Officer now directly owns 93,536 shares in the company, valued at $9.31 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23 ’25, Officer Bonstein Sara bought 57,765 shares of the business’s stock. A total of $5,877,434 was incurred on buying the stock at an average price of $101.75. A total of 2.23% of the company’s stock is owned by insiders.
During the past 12 months, Insmed Inc has had a low of $60.40 and a high of $106.83. As of last week, the company has a debt-to-equity ratio of 13.21, a current ratio of 5.86, and a quick ratio of 5.44. The fifty day moving average price for INSM is $77.5188 and a two-hundred day moving average price translates $74.6791 for the stock.
The latest earnings results from Insmed Inc (NASDAQ: INSM) was released for 2025-03-31. The net profit margin was -265.93% and return on equity was -890.75% for INSM. The company reported revenue of $92.82 million for the quarter, compared to $75.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.94 percent.
